Wells Fargo’s Alzamend Neuro ALZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-111
Closed -$1.69K – 7049
2024
Q3
$1.69K Buy
+111
New +$2.9K ﹤0.01% 6071
2024
Q2
– Hold
0
– -$39 – 6886
2024
Q1
– Hold
0
– – – 6888
2023
Q4
– Hold
0
– – – 7059
2023
Q3
– Hold
0
– – – 6727
2023
Q2
– Hold
0
– – – 6682
2023
Q1
– Sell
-1
Closed -$752 – 6821
2022
Q4
$785 Buy
+1
New +$1.45K ﹤0.01% 6261
2022
Q3
– Hold
0
– – – 6611
2021
Q3
– Hold
0
– -$2K – 6928
2021
Q2
– Hold
0
– – – 6519

Other funds holding ALZN

Wells Fargo's ALZN Position: Q4 2024 in Review

Wells Fargo sold out of Alzamend Neuro (ALZN) in Q4 2024, closing a stake of 111 shares — an estimated $1.69K sold.

Wells Fargo first reported a position in ALZN in Q4 2022 and held it in 2 quarters. The position peaked at $1.69K in Q3 2024. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2024.

  • Wells Fargo reported no remaining Alzamend Neuro position as of Q4 2024 after selling out during the quarter.
  • Wells Fargo sold 111 Alzamend Neuro shares in Q4 2024, an estimated $1.69K.
  • Wells Fargo first reported a position in Alzamend Neuro in Q4 2022 and held it in 2 quarters.
  • Wells Fargo's Alzamend Neuro position peaked at $1.69K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2024.

Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.